Strata Critical Medical says fiscal Q2 ended June 30, 2026 results driven by accelerating Clinical revenue growth and higher margins
SRTA•Updated guidance
Guidance was raised to $285 million to $295 million in revenue and $33 million to $35 million in Adjusted EBITDA; a 3% Logistics revenue headwind is expected in Q3.
Q2 revenue growth and margin expansion
Strata Critical Medical posted Q2 2026 revenue of $72.5 million, up 60.7%, driven by Clinical growth and recent acquisitions.
Clinical revenue rose 22.6% sequentially to $24.3 million; organic Clinical growth was 15.1%, led by 23.8% growth in Transplant Clinical.
Clinical gross margin improved to 26.1% from 25.0%; total gross margin rose to 21.0% as mix shifted toward higher-margin Clinical services.
Logistics performance and margin pressure
Logistics revenue rose about 1% sequentially; gross margin fell to 18.4% on fuel surcharge effects, short-trip mix, maintenance costs, and lower ground margins.
